Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.9K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Tissue Transplantation01:24

Tissue Transplantation

1.4K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A prospective study with Comprehensive Geriatric Assessment (CGA) before curative treatment in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Oral oncology·2026
Same author

Validation of a prognostic nomogram for locally advanced oropharyngeal carcinoma treated with intensity-modulated radiotherapy with/without systemic therapy.

ESMO open·2025
Same author

KEYNOTE-689: A step forward or a leap of faith in resectable LA-HNSCC?

Oral oncology·2025
Same author

(CAR-)T cell dynamics following chimeric antigen receptor T cells for large B cell lymphoma: a translational tale.

Leukemia & lymphoma·2025
Same author

Effect of HLA mismatch on post-transplant infections in allogeneic hematopoietic stem cell transplantation with PTCy-based GvHD prophylaxis.

Bone marrow transplantation·2023
Same author

Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation.

Annals of hematology·2022

Related Experiment Video

Updated: Apr 22, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K

DLI after haploidentical BMT with post-transplant CY.

A Ghiso1, A M Raiola1, F Gualandi1

  • 1Divisione Ematologia e Trapianto di Midollo, IRCCS San Martino, Genova, Italy.

Bone Marrow Transplantation
|October 14, 2014
PubMed
Summary

Escalating doses of donor lymphocyte infusions (DLI) are safe after haploidentical stem cell transplants with post-transplant cyclophosphamide (PT-CY). Response rates and survival vary by disease, highlighting DLI

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.3K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

6.8K

Related Experiment Videos

Last Updated: Apr 22, 2026

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

17.2K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.3K
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

6.8K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Relapse after unmanipulated haploidentical stem cell transplantation with post-transplant cyclophosphamide (PT-CY) remains a clinical challenge.
  • Donor lymphocyte infusions (DLI) are a potential strategy to overcome relapse by leveraging graft-versus-leukemia effects.
  • Optimizing DLI dosing and administration in the haploidentical setting requires further investigation.

Purpose of the Study:

  • To evaluate the safety and efficacy of escalating doses of DLI in patients relapsing after haploidentical BM transplant and PT-CY.
  • To assess the impact of DLI on response rates and survival across different hematologic malignancies.
  • To determine the incidence of graft-versus-host disease (GVHD) associated with DLI administration.

Main Methods:

  • Forty-two patients with relapsed leukemias or Hodgkin's disease post-haploidentical BM transplant and PT-CY received 108 DLI.
  • DLI were administered at escalating doses (1 x 10^3 to 1 x 10^7 CD3+ cells/kg) without GVHD prophylaxis.
  • Patients received DLI alone or in combination with chemotherapy or azacytidine based on disease status and relapse type.

Main Results:

  • Escalating DLI doses were safely administered, with a low incidence of acute GVHD (10-15%) across treatment groups.
  • Overall response rates varied: 45% for molecular relapse leukemias, 33% for hematologic relapse leukemias, and 70% for Hodgkin's disease.
  • Two-year actuarial survival rates were 43% (molecular relapse), 19% (hematologic relapse), and 80% (Hodgkin's disease).

Conclusions:

  • Escalating doses of DLI can be safely administered in the haploidentical setting with PT-CY, demonstrating a manageable GVHD risk.
  • Treatment response and survival outcomes following DLI are significantly influenced by the underlying hematologic malignancy and relapse status.
  • DLI represents a viable therapeutic option for relapsed hematologic malignancies post-haploidentical transplantation, with tailored approaches needed for optimal results.